What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?
Bosi, Guilherme Rasia, Fogliatto, Laura Maria, Costa, Tito Emilio Vanelli, Grokoski, Kamila Castro, Pereira, Mariana Pinto, Bugs, Nathan, Kalil, Marco, Fraga, Christina, Daudt, Liane Esteves, Silla, Lucia Mariano da Rocha
Published in Hematology, Transfusion and Cell Therapy (01.07.2019)
Published in Hematology, Transfusion and Cell Therapy (01.07.2019)
Get full text
Journal Article